drugset / Trial / NCT04656028

Genetic Testing and Motivational Counseling for FH

NCT04656028

RandomizedParallel-groupSingle-blindTreatment

Summary

To date, there are highly effective lipid-lowering drugs, the combination of which makes it possible to achieve the target level of LDL-C in most patients with familial hypercholesterolemia (FH). However, the effectiveness of treatment of FH patients strongly depends on adherence to lipid-lowering therapy and to the healthy lifestyle, as well as the detection of the disease and the therapy prescription as early as possible, better in childhood. The aim of the study is to assess the impact of genetic testing and motivational counseling on the effectiveness of treatment and cascade screening in patients with FH.

Timeline

Start
2020-06-15
Primary completion
2025-01-30
Completion
2025-03-30

Drugs

EvaluationDrugModalityDoseRoute
Background Alirocumab Monoclonal antibody
Background Atorvastatin Small molecule
Background Evolocumab Monoclonal antibody
Background Ezetimibe Unknown
Background Rosuvastatin Small molecule